Bad Precedent? Plan B Dual Labeling Could Impact Existing OTCs – NEJM
This article was originally published in The Tan Sheet
Dual Rx/OTC labeling for the Plan B emergency contraceptive may have similar implications for medications that are already available over the counter, according to an editorial in the June 3 New England Journal of Medicine
You may also be interested in...
Barr hinted that it is leaning toward a dual label Rx/OTC approach in seeking FDA approval to switch the Plan B "morning after" pill
Barr Labs submitted a marketing plan for behind-the-counter sale of Plan B (levonorgestrel .75 mg), but FDA was "unable" to review the package
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC